6533b7d3fe1ef96bd1260a3e

RESEARCH PRODUCT

Diagnosis of silent coronary ischemia with selective coronary revascularization might improve 2-year survival of patients with critical limb-threatening ischemia.

Madara BruvereRoberts RumbaSanda JegereEdgars ZellansIndulis KumsarsDainis KrievinsChristopher K. ZarinsGustavs Latkovskis

subject

Malemedicine.medical_specialtyTime FactorsComputed Tomography AngiographyCritical IllnessIschemiaFractional flow reserveCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyRisk AssessmentCoronary artery disease03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineIschemiaPredictive Value of TestsRisk FactorsInternal medicinemedicineMyocardial RevascularizationHumans030212 general & internal medicineMyocardial infarctionProspective StudiesStrokeAgedbusiness.industryHazard ratioCoronary ischemiaMiddle Agedmedicine.diseaseLimb SalvageFractional Flow Reserve MyocardialStenosisTreatment OutcomeCase-Control StudiesAsymptomatic DiseasesCardiologySurgeryFemaleCardiology and Cardiovascular Medicinebusiness

description

Abstract Background Patients with critical limb-threatening ischemia (CLTI) have had poor long-term survival after lower extremity revascularization owing to coexistent coronary artery disease. A new cardiac diagnostic test, coronary computed tomography-derived fractional flow reserve (FFRCT), can identify patients with ischemia-producing coronary stenosis who might benefit from coronary revascularization. We sought to determine whether the diagnosis of silent coronary ischemia before limb salvage surgery with selective postoperative coronary revascularization can reduce the incidence of adverse cardiac events and improve the survival of patients with CLTI compared with standard care. Methods Patients with CLTI and no cardiac history or symptoms who had undergone preoperative testing to detect silent coronary ischemia with selective postoperative coronary revascularization (group I) were compared with patients with standard preoperative cardiac clearance and no elective postoperative coronary revascularization (group II). Both groups received guideline-directed medical care. Lesion-specific coronary ischemia in group I was defined as FFRCT of ≤0.80 distal to a stenosis, with severe ischemia defined as FFRCT of ≤0.75. The endpoints included all-cause death, cardiovascular (CV) death, myocardial infarction (MI), major adverse CV events (i.MACE; CV death, MI, unplanned coronary revascularization, stroke) through 2 years of follow-up. Results Groups I (n = 111) and II (n = 120) were similar in age (66 ± 9 vs 66 ± 7 years), gender (78% vs 83% men), comorbidities, and surgery performed. In group I, unsuspected, silent coronary ischemia was found in 71 of 103 patients (69%), with severe ischemia in 58% and left main coronary ischemia in 8%. Elective postoperative coronary revascularization was performed in 47 of 71 patients with silent ischemia (66%). In group II, the status of silent coronary ischemia was unknown. The median follow-up was >2 years for both groups. The 2-year outcomes for groups I and II were as follows: all-cause death, 8.1% and 20.0% (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.18-0.84; P = .016); CV death, 4.5% and 13.3% (HR, 0.32; 95% CI, 0.11-0.88; P = .028); MI, 6.3% and 17.5% (HR, 0.33; 95% CI, 0.14-0.79; P = .012); and major adverse CV events, 10.8% and 23.3% (HR, 0.44; 95% CI, 0.22-0.88; P = .021), respectively. Conclusions The preoperative evaluation of patients with CLTI and no known coronary artery disease using coronary FFRCT revealed silent coronary ischemia in two of every three patients. Selective coronary revascularization of patients with silent coronary ischemia after recovery from limb salvage surgery resulted in fewer CV deaths and MIs and improved 2-year survival compared with patients with CLTI who had received standard cardiac evaluation and care. Prospective controlled studies are required to further define the role of FFRCT in the evaluation and treatment of patients with CLTI.

10.1016/j.jvs.2021.03.059https://pubmed.ncbi.nlm.nih.gov/33905868